Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATI-045 · 1 trial · 5 indications
Percent change from baseline in EASI score at Week 24
| Arm | Type | Description |
|---|---|---|
| ATI-045 group | EXPERIMENTAL | ATI-045 group |
| Placebo group | PLACEBO_COMPARATOR | Placebo group |
| Name | Type | Description |
|---|---|---|
| ATI-045 | DRUG | ATI-045 group |
| Placebo | DRUG | Placebo group |
Inclusion Criteria: * Diagnosis of chronic atopic dermatitis that has been present for ≥ 6 months before the screening visit and with no significant AD flares during the past 4 weeks before screening * Have active moderate to severe AD at screening and baseline visits * EASI score ≥ 16 and ≥10% BSA...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | 611 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
ATI-045 is an investigational small molecule being developed for the treatment of moderate-to-severe atopic dermatitis, also known as eczema. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
ATI-045 targets TSLP, a cytokine involved in inflammatory responses. By targeting TSLP, the drug aims to modulate the immune pathways implicated in atopic dermatitis. This mechanism is being evaluated in clinical trials for patients with moderate-to-severe disease.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is developing ATI-045. The company is conducting a Phase 2 clinical trial of the drug in patients with moderate-to-severe atopic dermatitis.
ATI-045 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. A Phase 2 trial is currently active but not recruiting participants.
ATI-045 is being studied in a Phase 2 trial with the identifier NCT07011706. This randomized, double-blind, placebo-controlled study enrolls approximately 110 adults with moderate-to-severe atopic dermatitis at sites in the United States and Canada.
No alternative names for ATI-045 have been disclosed. It is a distinct investigational small molecule being developed by Aclaris Therapeutics for atopic dermatitis.